Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q1 2025 value amounting to $4.4 million.

  • Monte Rosa Therapeutics' Other Accumulated Expenses rose 10467.59% to $4.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $4.4 million, marking a year-over-year increase of 10467.59%. This contributed to the annual value of $3.4 million for FY2024, which is 10071.81% up from last year.
  • According to the latest figures from Q1 2025, Monte Rosa Therapeutics' Other Accumulated Expenses is $4.4 million, which was up 10467.59% from $3.4 million recorded in Q4 2024.
  • Over the past 5 years, Monte Rosa Therapeutics' Other Accumulated Expenses peaked at $4.4 million during Q1 2025, and registered a low of $1.3 million during Q3 2024.
  • Its 3-year average for Other Accumulated Expenses is $2.7 million, with a median of $2.5 million in 2023.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 5519.26% in 2024, then skyrocketed by 10467.59% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.7 million in 2023, then surged by 100.72% to $3.4 million in 2024, then skyrocketed by 31.81% to $4.4 million in 2025.
  • Its Other Accumulated Expenses stands at $4.4 million for Q1 2025, versus $3.4 million for Q4 2024 and $1.3 million for Q3 2024.